癌立佳持續性藥效皮下注射劑7.5毫克
Country: Taiwan
Language: Chinese
Source: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
Patient Information leaflet
(PIL)
05-09-2022
Public Assessment Report
(PAR)
01-04-2020
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
LEUPRORELIN ACETATE
Available from:
健喬信元醫藥生技股份有限公司 新竹縣湖口鄉工業一路6號 (43199950)
ATC code:
L02AE02
Pharmaceutical form:
凍晶注射劑
Composition:
主成分 (Delivered dose in constituted drug product：) ; LEUPRORELIN ACETATE (6818000810) (Each Syringe B contains 10.6MG of Leuprorelin Acetate)MG
Units in package:
每組含2支(A溶劑+B藥品)預充填式注射針筒及1支20號無菌注射針頭，紙盒裝
Class:
製 劑
Prescription type:
限由醫師使用
Manufactured by:
ISOMEDIX OPERATIONS, INC. 9, APOLLO DRIVE WHIPPANY, NJ07981 USA US
Therapeutic area:
leuprorelin
Therapeutic indications:
用於晚期前列腺癌紓解治療，以及與放射治療併用於高風險的局部和局部晚期荷爾蒙依賴型前列腺癌治療。
Product summary:
有效日期: 2024/04/28; 英文品名: Eligard 7.5 mg, powder and solvent for solution for injection
Authorization date:
2014-04-28
Patient Information leaflet
04006197_Rev. 2_TW_Eligard_CI_20220422.ai 1
04006197_Rev. 2_TW_Eligard_CI_20220422.ai
04006197 Rev. 2 04/22
April 22, 2022
04006197 Rev. 2 04/22
新竹縣湖口鄉工業一路6號
04006197_Rev. 2_TW_Eligard_CI_20220422.ai
04006197 Rev. 2 04/22
April 22, 2022
04006197_Rev. 2_TW_Eligard_CI_20220422.ai 2
Read the complete document
